Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
After the infant’s birth, the neonatologist’s first duty is to his or her patient—the newly born infant. If clinical circumstances are different than anticipated, the physician must first consider the best interests of the baby.
Transparency about teaching hospitals’ educational mission respects patient autonomy and aligns patients’ interests with those of trainees and the public.
AMA J Ethics. 2017;19(6):537-543. doi:
10.1001/journalofethics.2017.19.6.ecas1-1706.
This month, AMA Journal of Ethics theme editor Jacquelyn Nestor, a fifth-year MD/PhD student at Hofstra-Northwell School of Medicine, interviewed Allen Buchanan, PhD, about how we can safely explore cutting-edge biomedical enhancements.